Hawaii’s Senate has passed a bill that would create a psychedelic task force tasked with studying and making policy recommendations on providing access to breakthrough therapies like psilocybin and MDMA.
After moving through the committee process, the full Senate on Friday approved Sen. Chris Lee’s (D) legislation by a 24-0 vote and sent it to the House of Representatives for consideration.
The measure would create the Emerging Mental Health Therapies Task Force, which for two years will review the current scientific literature, support additional clinical research, and develop policy recommendations for the “safe, ethical, and culturally informed implementation” of a psychedelic therapy program.
“The Legislature believes in addressing the mental health crisis affecting the State’s residents, particularly among veterans, first responders and trauma survivors,” SB 3199 reads. “Suicide remains the leading cause of preventable death, and the State must explore all safe and effective treatment options supported by scientific evidence.”
Given that the Federal Food and Drug Administration (FDA) has designated psilocybin and MDMA as breakthrough therapies in the treatment of serious mental health conditions, which may be subject to future control under the Controlled Substances Act (CSA), Hawaii’s legislation states that the state must “proactively prepare public health, clinical and research systems for safe and equitable implementation.”
Team members should include representatives from the State Department of Health (DOH), the Office of the Attorney General, the Office of Wellness and Resiliency (OWR), the University of Hawaii School of Medicine, and more.
As in the draft, the task force was to be overseen by the DOH, but this was changed in the commission to be “the responsibility of an entity with proven experience in primary scientific research and pharmaceutical or medical education.”
“The administrative work of the task force within an entity with proven experience in primary scientific research and pharmaceutical or medical teaching shall not be construed to transfer, delegate, reduce, extend, or otherwise modify any regulatory, enforcement, licensing, programming, or regulatory authority vested in the Department of Health, the Board of Pharmacy, or any other billing agency. “All statutory authority relating to controlled substances, professional licensing, and public health regulations is provided by law. They will be left to the appropriate executive authorities.”
It seems invoice would be It was first assembled in 2023 based on prior work by a separate psychedelic task force.With a similar goal of exploring avenues for therapeutic access in breakthrough drugs approved by the FDA such as psilocybin.
—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.
Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—
Meanwhile, Hawaii senators recently passed a bill to legalize low-dose, low-potency marijuanaalthough members of the House of Representatives say that the ban on cannabis will not end this year in the state.
A separate marijuana legalization bill, SB 2421, that contained provisions under federal reform law or amendments to the state Constitution, was delayed for action. The Senate and House panels also delayed action on a measure to sell certain hemp-derived cannabinoid products.
Senate committee action follows Senior lawmakers in the House indicated that proposals to legalize cannabis would not move forward In the 2026 session, citing the lack of sufficient support in their chamber.
On Thursday, another Hawaii Senate committee separately approved legislation to allow patients immediately enter medical cannabis after submitting their recordsinstead of waiting for the cards to be delivered, as is the case under current legislation.
user photo CostaPPR.